Developing the INCLUDE Ethnicity Framework-a tool to help trialists design trials that better reflect the communities they serve.
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
10 May 2021
10 May 2021
Historique:
received:
22
01
2021
accepted:
16
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Ensuring that a trial is designed so that its participants reflect those who might benefit from the results, or be spared harms, is key to the potential benefits of the trial reaching all they should. This paper describes the process, facilitated by Trial Forge, that was used between July 2019 and October 2020 to develop the INCLUDE Ethnicity Framework, part of the wider INCLUDE initiative from the National Institute for Health Research to improve inclusion of under-served groups in clinical research studies. Development of the Framework was done in seven phases: (1) outline, (2) initial draft, (3) stakeholder meeting, (4) modify draft, (5) Stakeholder feedback, (6) applying the Framework and (7) packaging. Phases 2 and 3 were face-to-face meetings. Consultation with stakeholders was iterative, especially phases 4 to 6. Movement to the next phase was done once all or most stakeholders were comfortable with the results of the current phase. When there was a version of the Framework that could be considered final, the Framework was applied to six trials to create a set of examples (phase 6). Finally, the Framework, guidance and examples were packaged ready for dissemination (phase 7). A total of 40 people from stakeholder groups including patient and public partners, clinicians, funders, academics working with various ethnic groups, trial managers and methodologists contributed to the seven phases of development. The Framework comprises two parts. The first part is a list of four key questions: 1. Who should my trial apply to? 2. Are the groups identified likely to respond in different ways? 3. Will my study intervention make it harder for some groups to engage? 4. Will the way I have designed the study make it harder for some groups to engage? The second part is a set of worksheets to help trial teams address these questions. The Framework can be used for any stage of trial, for a healthcare intervention in any disease area. The Framework was launched on 1st October 2020 and is available open access at the Trial Forge website: https://www.trialforge.org/trial-forge-centre/include/ . Thinking about the number of people in our trials is not enough: we need to start thinking more carefully about who our participants are.
Sections du résumé
BACKGROUND
BACKGROUND
Ensuring that a trial is designed so that its participants reflect those who might benefit from the results, or be spared harms, is key to the potential benefits of the trial reaching all they should. This paper describes the process, facilitated by Trial Forge, that was used between July 2019 and October 2020 to develop the INCLUDE Ethnicity Framework, part of the wider INCLUDE initiative from the National Institute for Health Research to improve inclusion of under-served groups in clinical research studies.
METHODS
METHODS
Development of the Framework was done in seven phases: (1) outline, (2) initial draft, (3) stakeholder meeting, (4) modify draft, (5) Stakeholder feedback, (6) applying the Framework and (7) packaging. Phases 2 and 3 were face-to-face meetings. Consultation with stakeholders was iterative, especially phases 4 to 6. Movement to the next phase was done once all or most stakeholders were comfortable with the results of the current phase. When there was a version of the Framework that could be considered final, the Framework was applied to six trials to create a set of examples (phase 6). Finally, the Framework, guidance and examples were packaged ready for dissemination (phase 7).
RESULTS
RESULTS
A total of 40 people from stakeholder groups including patient and public partners, clinicians, funders, academics working with various ethnic groups, trial managers and methodologists contributed to the seven phases of development. The Framework comprises two parts. The first part is a list of four key questions: 1. Who should my trial apply to? 2. Are the groups identified likely to respond in different ways? 3. Will my study intervention make it harder for some groups to engage? 4. Will the way I have designed the study make it harder for some groups to engage? The second part is a set of worksheets to help trial teams address these questions. The Framework can be used for any stage of trial, for a healthcare intervention in any disease area. The Framework was launched on 1st October 2020 and is available open access at the Trial Forge website: https://www.trialforge.org/trial-forge-centre/include/ .
CONCLUSION
CONCLUSIONS
Thinking about the number of people in our trials is not enough: we need to start thinking more carefully about who our participants are.
Identifiants
pubmed: 33971916
doi: 10.1186/s13063-021-05276-8
pii: 10.1186/s13063-021-05276-8
pmc: PMC8108025
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337Subventions
Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V020544/1
Pays : United Kingdom
Références
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
Int J Equity Health. 2019 Dec 31;19(1):2
pubmed: 31892328
Trials. 2020 Aug 1;21(1):694
pubmed: 32738919
BMC Nephrol. 2013 Sep 26;14:201
pubmed: 24067062
Cancer. 2014 Apr 1;120 Suppl 7:1091-6
pubmed: 24643646
J Med Internet Res. 2016 Sep 26;18(9):e256
pubmed: 27670360
BMC Med. 2020 May 18;18(1):133
pubmed: 32418543
Lancet. 2020 Jun 27;395(10242):1955-1957
pubmed: 32539937
Diabet Med. 2017 Jan;34(1):64-68
pubmed: 26926478
Postgrad Med J. 2005 Mar;81(953):141-7
pubmed: 15749788
Diabetes. 2015 May;64(5):1786-93
pubmed: 25510240
J Viral Hepat. 2011 Apr;18(4):e134-43
pubmed: 21108699